Localized Prostate Cancer Clinical Trial
Official title:
Post-marketing Clinical Study of Transrectal High-intensity Focused Ultrasound for Localized Prostate Cancer
In this study, the safety and effectiveness data of Sonablate system, a transrectal high-intensity focused ultrasound therapeutic instrument, in the treatment of localized prostate cancer were collected, and the treatment conditions of patients with other methods (such as radical prostatectomy) were compared and analyzed. Observe the differences in treatment effect, survival rate, postoperative PSA, recurrence and complications. To analyze and compare the clinical outcome, postoperative complications and tumor control of HIFU and robot-assisted laparoscopic radical prostatectomy for localized prostate cancer, and to explore the effectiveness and safety of HIFU in the treatment of localized prostate cancer, so as to provide an alternative treatment for localized prostate cancer.
This observational study will collect medical history and questionnaire data before and after high intensity focused ultrasound (HIFU) or radical surgery to perform local ablation or excision of prostate cancer tissue. This study established a cohort of relevant subjects and collected their postoperative follow-up data. The study was divided into two groups: - Study group: Transrectal high intensity focused ultrasound (HIFU) therapy; - Control group: robot-assisted laparoscopic radical prostatectomy (RALP). Compare and analyze the treatment status of the same period of patients treated by the study group or the control group, observe the differences in treatment effect, survival rate, postoperative PSA, recurrence and complications, and explore the effectiveness and safety of HIFU treatment for localized prostate cancer. Electronic medical records of prostate cancer patients who received Sonablate® high intensity focused ultrasound (HIFU) and robot-assisted laparoscopic radical prostatectomy at Renji Hospital, Shanghai Jiao Tong University School of Medicine from 2021 to the end of the study were collected and analyzed. Baseline characteristics, postoperative complications and disease control rate were evaluated.In this study, patients clinically diagnosed with localized prostate cancer were classified into low - and medium-risk groups to receive local HIFU treatment or robot-assisted laparoscopic radical prostatectomy (RALP) from March 2021 to the end of the study through medical history review. Patient age, PSA value at the time of diagnosis of prostate cancer, and whether they received short-term antiandrogen therapy before treatment were collected. The changes of PSA levels in each group were dynamically observed after surgery, mp-MRI was performed under the guidance of ultrasound-guided, and the negative rate was calculated. Phoenix was defined as biochemical recurrence (PSA ≥2 ng/mL higher than the lowest point), and the patient experience (postoperative complications and quality of life) after HIFU and robot-assisted laparoscopic radical prostatic resection were compared. Write clinical evaluation report. Patients meeting the inclusion criteria were divided into the control group [receiving robot-assisted laparoscopic radical prostatectomy (RALP)] and the study group [receiving high-intensity focused ultrasound (HIFU)]. A cohort of relevant patients was established and postoperative follow-up data were collected. The relevant outcome indicators and clinical indicators before and after treatment were compared between the two groups. To clarify the clinical value of high-intensity focused ultrasound in local treatment of localized prostate cancer, and further explore the related prognostic factors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03996005 -
MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
|
N/A | |
| Withdrawn |
NCT02159690 -
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
|
Phase 2 | |
| Completed |
NCT00196781 -
Treatment Decision Making in Early-Stage Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT03821246 -
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
|
Phase 2 | |
| Active, not recruiting |
NCT03814252 -
Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer
|
N/A | |
| Completed |
NCT01931046 -
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01714219 -
Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy
|
N/A | |
| Active, not recruiting |
NCT03315754 -
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
|
Phase 2 | |
| Recruiting |
NCT05010343 -
Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06325995 -
Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer
|
N/A | |
| Recruiting |
NCT06051942 -
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
|
N/A | |
| Completed |
NCT02297386 -
[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06117059 -
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
|
N/A | |
| Withdrawn |
NCT04225299 -
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT06054867 -
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
|
N/A | |
| Active, not recruiting |
NCT02435472 -
Active Surveillance Exercise Clinical Trial
|
N/A | |
| Completed |
NCT00717613 -
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
|
N/A | |
| Completed |
NCT02662673 -
Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device
|
N/A | |
| Recruiting |
NCT05155046 -
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
|
Phase 2 | |
| Completed |
NCT01902680 -
Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.
|
Phase 2 |